JVM Co (054950) Fair Value & Analysis
Healthcare · KR · Market cap 257B KRW
Fair value as of: Jul 22, 2026
From 24 valuation models · updated 19 days ago
Share price +13.9% over the past month.
A solid business, screening 68% undervalued on our models.
What matters now
- The price is below even our cautious bear case (30,217 KRW). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (30,217 KRW to 60,210 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 11,782 KRW – 36,765 KRW · fair‑value band 30,217 KRW – 60,210 KRW · the 24,950 KRW price screens below the 41,845 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
JVM Co (054950) currently trades at 24,950 KRW, while our model-based Fair Value estimate is 41,845 KRW, implying the stock looks roughly 67.7% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, JVM Co generated revenue of 176B KRW at a net margin of 16.0%. Revenue grew 6.2% year over year. It earns a return on equity of 12.9%. Net debt stands at 22.5B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 30,217 KRW (bear case) to 60,210 KRW (bull case); at 24,950 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 26% below its 52-week high and 19% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at 68%, 054950 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (46,316 KRW) versus Asset-Based (13,609 KRW). Highest evidence: Growth DCF (80).
Notify me when 054950 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
JVM Co., Ltd. develops and sells automation systems and software of dispensing, packaging, and medication management for hospitals and pharmacies worldwide.
Full company description
JVM Co., Ltd. develops and sells automation systems and software of dispensing, packaging, and medication management for hospitals and pharmacies worldwide. It offers automatic dispensing and packaging systems; medication inspection and winding systems; medicine counting systems; canister management systems; automatic tablet counting systems; automatic tablet cutting systems; automatic PTP deblisters; special shape tablets pre-preparation systems; automatic pouch rolling systems; DOB blister paper sealing guides; and automated medication management systems. The company also provides OnCube Management for dispensing, packaging, and medication management; Check VIZEN, a pouch inspection and management software; STS Load Station, an STS pre-packaging software; INTIPharm Management, a medication management software; INTIPharm Notifier, a medication management alert software; INTIPharm Transfer Check, a medication management transfer software; and INTIPharm Secusion Viewer, a medication management image viewer software. In addition, it is involved in the sales of automatic drug sorting and packaging systems. The company was formerly known as JVMedi and changed its name to JVM Co., Ltd. in April 2004. JVM Co., Ltd. was founded in 1977 and is headquartered in Daegu, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
JVM Co reported revenue of 173B KRW in FY2025 versus 116B KRW in FY2021, a compound +10.6%/yr. Reported net income was 28.4B KRW in FY2025, compounding +33.4%/yr from FY2021.
Watch 054950: get an alert when its fair value changes →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare JVM Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is JVM Co (054950) overvalued or undervalued?
What is the fair value of 054950?
What is the quality score of 054950?
What is the revenue of JVM Co (054950)?
What is the net profit margin of 054950?
Does JVM Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track JVM Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.